Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Current Assets: 2015-2025

Historic Current Assets for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to $147.3 million.

  • Cartesian Therapeutics' Current Assets fell 35.73% to $147.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.3 million, marking a year-over-year decrease of 35.73%. This contributed to the annual value of $216.6 million for FY2024, which is 138.76% up from last year.
  • Cartesian Therapeutics' Current Assets amounted to $147.3 million in Q3 2025, which was down 9.87% from $163.4 million recorded in Q2 2025.
  • Cartesian Therapeutics' Current Assets' 5-year high stood at $229.1 million during Q3 2024, with a 5-year trough of $89.9 million in Q3 2023.
  • In the last 3 years, Cartesian Therapeutics' Current Assets had a median value of $138.4 million in 2023 and averaged $147.2 million.
  • In the last 5 years, Cartesian Therapeutics' Current Assets spiked by 173.23% in 2021 and then tumbled by 43.72% in 2023.
  • Quarterly analysis of 5 years shows Cartesian Therapeutics' Current Assets stood at $144.4 million in 2021, then climbed by 2.56% to $148.1 million in 2022, then plummeted by 38.75% to $90.7 million in 2023, then soared by 138.76% to $216.6 million in 2024, then plummeted by 35.73% to $147.3 million in 2025.
  • Its Current Assets stands at $147.3 million for Q3 2025, versus $163.4 million for Q2 2025 and $185.1 million for Q1 2025.